v3.26.1
Contract revenues and other operating income - Anti-Abeta Active Immunotherapy in AD - 2024 agreement Takeda Pharmaceuticals, USA Inc. (Details)
SFr in Thousands, $ in Millions
1 Months Ended 6 Months Ended
May 31, 2024
CHF (SFr)
May 31, 2024
USD ($)
Jun. 30, 2026
CHF (SFr)
Jun. 30, 2025
CHF (SFr)
May 31, 2024
USD ($)
Disclosure of disaggregation of revenue from contracts with customers [line items]          
Contract revenue     SFr 16,232 SFr 2,296  
Anti-Abeta Active Immunotherapy in AD- 2024 agreement Takeda Pharmaceuticals, USA, Inc.          
Disclosure of disaggregation of revenue from contracts with customers [line items]          
Collaborative agreement, upfront payments received SFr 92,300 $ 100.0      
Period to provide notice of termination of agreement 90 days 90 days      
Transaction price SFr 92,300       $ 100.0
Number of development milestones that may occur prior to option exercise included in transaction price 0       0
Contract revenue     2,100    
Deferred revenue     SFr 84,000    
Anti-Abeta Active Immunotherapy in AD- 2024 agreement Takeda Pharmaceuticals, USA, Inc. | License option and development, CMC and regulatory activities          
Disclosure of disaggregation of revenue from contracts with customers [line items]          
Transaction price SFr 92,300       $ 100.0
Anti-Abeta Active Immunotherapy in AD- 2024 agreement Takeda Pharmaceuticals, USA, Inc. | License option          
Disclosure of disaggregation of revenue from contracts with customers [line items]          
Transaction price SFr 80,700       87.4
Anti-Abeta Active Immunotherapy in AD- 2024 agreement Takeda Pharmaceuticals, USA, Inc. | Development, CMC and regulatory activities          
Disclosure of disaggregation of revenue from contracts with customers [line items]          
Number of performance obligations identified 1 1      
Transaction price SFr 11,600       12.6
Anti-Abeta Active Immunotherapy in AD- 2024 agreement Takeda Pharmaceuticals, USA, Inc. | Maximum          
Disclosure of disaggregation of revenue from contracts with customers [line items]          
Collaborative agreement, potential amount receivable if certain conditions are fulfilled SFr 1,700,000       $ 2,100.0